CLDX CELLDEX THERAPEUTICS INC Other Situations 8-K Filing 2023 - Clarification on PN Study Celldex Therapeutics, Inc. clarifies that their Phase 1b study and clinical development of barzolvolimab in prurigo nodularis (PN) was not terminated due to a serious adverse event, and they plan to continue developing the drug for PN.Get access to all SEC 8-K filings of the CELLDEX THERAPEUTICS INC